BMS-754807

Phase 2Small molecule

Bristol-Myers Squibb

BMS-754807 is one of 54 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

ObesityActive, not recruiting

Maturity-Onset Diabetes of the YoungActive, not recruiting

Breast CancerPhase 2

Active, not recruiting

ObesityPhase 2

Active, not recruiting

Maturity-Onset Diabetes of the YoungPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tykerb

GSK

Preclinical

80 2

Adriamycin

GGynecologic Oncology Group

Preclinical

87 3

Avastin

Prolia

14 5

Gemzar

GGynecologic Oncology Group

Preclinical

22 6

BMS-754807

Bristol-Myers Squibb

Phase 2

2 7

Voltaren

Novartis

Preclinical

1 8

Blenoxane

Bristol-Myers Squibb

Preclinical

1 9

Chirocaine

PPurdue Pharma LP

Preclinical

1 10

Vfend

PPrism Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced or Metastatic Solid Tumors3 trials

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00793897·21 enrolled

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00908024·54 enrolled

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00569036·63 enrolled

Breast Cancer2 trials

Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00788333·40 enrolled

Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01225172·77 enrolled

Metformin1 trial

Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With Metformin

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01525823·26 enrolled

Patients With Solid Tumors1 trial

Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00898716·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for BMS-754807. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMS-754807 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMS-754807. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

BMS-754807

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Advanced or Metastatic Solid Tumors3 trials

Breast Cancer2 trials

Metformin1 trial

Patients With Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News